Benzinga | Jul 19, 2021 01:16PM EDT

BioMarin Unveils News Data From Late-Stage Hemophilia A Gene Therapy Candidate

* BioMarin Pharmaceutical Inc (NASDAQ:BMRN) has announced new data from GENEr8-1 Phase 3 study for valoctocogene roxaparvovec, investigational gene therapy for severe hemophilia A.

* Data were presented at the International Society on Thrombosis and Haemostasis (ISTH) 2021 Virtual Congress.

* Top-line one-year results from this study were previously communicated in January 2021.

* New data presented include more details on annualized bleeding rate (ABR) in all study participants and annualized Factor VIII utilization rate.

* Over 90% (N=134) of all participants in the GENEr8-1 study had an ABR of zero or a lower bleed rate than baseline after week four after the treatment.

* Mean annualized Factor VIII utilization rate decreased from baseline on Factor VIII prophylaxis by 99% from 3961.2 to 56.9 after week four after treatment with valoctocogene roxaparvovec.

* As previously shared in January 2021, a single dose of valoctocogene roxaparvovec significantly reduced mean ABR by 84% from a prospectively collected 4.8 baseline to 0.8 bleeding episodes per year.

* Study participants also experienced a clinically meaningful increase in endogenous Factor VIII expression.

* Last week, the European Medicines Agency validated BioMarin's resubmission of a marketing application for the gene therapy.